Quest Diagnostics Study Links Bacterial Vaginosis to Higher STI Co-Infection Rates
Event summary
- Quest Diagnostics and Hologic analyzed data from 1.5 million women, finding 38.7% positive for bacterial vaginosis (BV) and 12% of those co-infected with at least one STI.
- BV-positive women had significantly higher odds of STIs: 2.8x for chlamydia, 3.8x for gonorrhea, 3.6x for trichomonas, and 1.9x for mycoplasma genitalium.
- The study was published in O&G Open, a peer-reviewed journal affiliated with Obstetrics & Gynecology.
- Quest introduced self-collection services for BV and other infections at over 2,000 patient service centers in 2024.
The big picture
This study underscores the growing recognition of BV as a risk factor for STIs, reinforcing the need for integrated diagnostic approaches. With nearly 30% of U.S. women experiencing BV, the findings could drive demand for advanced molecular testing solutions. Quest's role in this research positions it as a key player in shaping evidence-based clinical guidelines.
What we're watching
- Diagnostic Adoption
- Whether the study accelerates clinician adoption of comprehensive molecular testing for BV and STI co-infections.
- Regulatory Impact
- How CDC guidelines may evolve to emphasize STI screening for BV-positive patients based on this evidence.
- Market Expansion
- The pace at which Quest scales its self-collection services, potentially expanding into other diagnostic areas.
Related topics